Thursday May 7, 2026 — Field Note

Thursday May 7, 2026 — Field Note

The Pathway
The PathwayMay 7, 2026

Key Takeaways

  • Ottava integrates four arms into a standard surgical table
  • FORTE study showed 30‑patient safety endpoint met at 30 days
  • System fits ORs as small as 243 sq ft, expanding market reach
  • J&J seeks de novo clearance for multiple general‑surgery procedures

Pulse Analysis

The debut of Johnson & Johnson’s Ottava platform marks a pivotal moment in soft‑tissue robotics, a field long dominated by Intuitive Surgical’s da Vinci system. By embedding four robotic arms directly into a conventional surgical table, Ottava sidesteps the bulky carts and boom‑mounts that have limited robot adoption to large, well‑funded hospitals. This architectural shift enables deployment in operating rooms as modest as 243 square feet, a size typical of many ambulatory surgery centers (ASCs) and community hospitals that have been priced out of robotic surgery.

In the FORTE feasibility study, 30 patients undergoing Roux‑en‑Y gastric bypass were treated across six U.S. sites, with no conversions to manual techniques and all primary safety and performance metrics met at the 30‑day mark. Although the trial is not a pivotal efficacy study, it provides the clinical foundation J&J needs for its de novo FDA submission, which seeks clearance for a suite of general‑surgery procedures including sleeve gastrectomy, small‑bowel resection, and hiatal hernia repair. The broader regulatory pathway, however, may be protracted, especially as the FDA’s device review teams operate with reduced staffing.

If Ottava can deliver comparable clinical outcomes while fitting into smaller ORs at a competitive price point, it could catalyze a wave of robotic adoption in settings previously excluded from the market. This would not only diversify revenue streams for J&J but also pressure incumbents like Intuitive to rethink their space‑heavy designs. The ultimate test will be whether hospitals—particularly ASCs—prioritize the flexibility Ottava offers over the established performance record of da Vinci, a decision that will shape the competitive landscape for years to come.

Thursday May 7, 2026 — Field Note

Comments

Want to join the conversation?